InsuSense Therapeutics


InsuSence Therapeutics (IST) is a product-focused biotechnology company based on novel breakthrough science in diabetes biology, which has the potential to quantum leap to important new Type 2 diabetes therapeutics. One of the most important features in the pathophysiology of Type 2 diabetes is insulin resistance. The IP position of the company consists of different natural circulating and cellular proteins that increase insulin action at the level of target tissues. It is the aim to refine these proteins into therapeutics acting as potent and safe insulin sensitizers for type 2 diabetes. IST considers a therapeutic principle addressing a key pathophysiological feature such as insulin resistance as an important medical breakthrough within Type 2 diabetes treatment.  This novel class of drugs clearly has blockbuster potential.

Type II diabetes is a significant problem

61.4 % of adults in England, for example, are overweight or obese, obesity represents a major public health issue. Obesity is known to increase the risk of a range of health problems, including insulin resistance and the subsequent development of type 2 diabetes mellitus. Insulin resistance occurs when an individual’s cells fail to respond normally to the hormone insulin. To overcome this, the pancreas (the organ responsible for producing insulin) compensates by producing more insulin to meet the metabolic demand. Ultimately, the levels of insulin produced are no longer adequate and therefore cellular glucose uptake is impaired, leading to hyperglycaemia and the likely development of diabetes mellitus.

The above diseases are not only an economic burden in their own right but can lead to multiple secondary disease states, further exacerbating the problem. Additionally, current pharmaceutical interventions fail to display adequate efficacy in a large proportion of patients, highlighting the need for novel treatment strategies.This is because type II diabetes is a complex pathology affecting multiple organs. Insusense has found a new mechanism in the fight against this disease. Our approach increases insulin sensitivity by acting at the validated target of insulin, namely, the insulin receptor. By increasing insulin sensitivity we reset the out of balance feedback systems and renormalize the metabolism.

Our mechanism of action revolves around the Vps10p proteins, a family of proteins that have been implicated in several diseases but clearly associated with insulin sensitivity.

The Vps10p domain proteins have intracellular trafficking functions – they move other proteins around the cell from the Golgi, where they are made, to the cell surface and then reinternalize proteins to recycle or lysosomal degradation.

In type II diabetes we can understand the interaction of our proteins with the insulin receptor, leading to increased insulin sensitivity.